Back to search

University of Ioannina

Διαστολική δυσλειτουργία της αριστερής κοιλίας στην κίρρωση: συχνότητα, διερεύνηση της συσχέτισης με την συστολική λειτουργία, την νεφρική λειτουργία και την κλινική έκβαση και ο ρόλος της ενδοτοξιναιμίας και των β-αποκλειστών

Abstract

dc:description

Title: “Left ventricular diastolic dysfunction in liver cirrhosis: prevalence and potential impact on systolic function, renal function and clinical outcome and the role of endotoxinemia and β-blockers ”Background: Left ventricular diastolic dysfunction (LVDD) is the most early and prevalent manifestation of cirrhotic cardiomyopathy, particularly among patients with ascites, while systolic function is usually normal at rest. Inflammatory activity has been suggested to be as the main pathogenetic mechanisms, however supporting evidence is limited. The long-term impact of LVDD on the occurrence of decompensating events, hepatorenal syndrome(HRS), and liver-related survival also remains unclear. The treatment of LVDD is currently unknown. Recent data suggested that the β-blocker carvedilol might improve LVDD in patients with cirrhosis. Objective: The current study aimed to evaluate the prevalence of LVDD in cirrhotic patients with and without ascites and to elucidate its association with systemic inflammation, systemic hemodynamics, effective arterial blood volume, and renal function and hemodynamics. We also investigated the association of the use of the β-blocker propranolol with the presence of LVDD and the long-term impact of converting propranolol to carvedilol on diastolic function among patients with ascites and LVDD. Finally, we assessed the risk125of decompensation events and HRS, and liver-related survival in the subgroup of patients with ascites according to their diastolic function. Methods: We prospectively enrolled 292 patients with cirrhosis, 215 with diuretic-responsive ascites and stable serum creatinine<1.5mg/dl and 77without ascites. All patients were seen at the outpatient hepatology clinics of University Hospital of Ioannina from May 2014 to May 2020. The diagnosis of LVDD was based on Doppler echocardiography according to 2009 American Society of Echocardiography recommendations as the presence of septal e’<8 cm/s and lateral e’<10 cm/s (e’: peak early diastolic mitral annular velocity). Left atrial volume index (LAVI) was also measured. The severity of LVDD was classified as follows: Grade 1: e’<8 cm/sec, E/e’ ratio≤8, E/A ratio<0.8, and DT>200 ms (E: early and A: atrial diastolic filling velocities; DT: deceleration time); Grade 2: e’<8 cm/sec, E/e’ ratio 9–12, E/A ratio 0.8–1.5,and DT 160–200 ms; and Grade 3: e’<8 cm/sec, E/e’ ratio≥13, E/A ratio≥2,and DT<160 ms. The systolic function was evaluated by the left ventricular ejection fraction (LVEF) at rest. An LVEF >50% was considered normal. Inflammatory markers (lipopolysaccharide-binding protein [LBP], tumornecrosis factor-a [TNF-a], interleukin-6 [Il-6]), systemic hemodynamics (meanarterial pressure [MAP], Doppler evaluated cardiac output [CO], systemic vascular resistance (SVR) as the ratio MAP/CO), vasoactive factors (plasmarenin activity [PRA], plasma aldosterone and noradrenaline), and radioisotope-assessed renal function (glomerular filtration rate [GFR] and hemodynamics (renal blood flow [RBF]) were assessed in patients with ascites. Patients with ascites and LVDD treated with propranolol were randomized at a ratio of 2:1 to switch to carvedilol 12.5mg daily for 6 months or continue propranolol and alterations in diastolic function along with the effects on systemic hemodynamics and renal function (estimated by the MDRD [Modification of Diet in Renal Disease]-6 equation) were recorded. The long-term occurrence of decompensating events, HRS development, and liver-related mortality were also evaluated. The patients were followed-up until death, liver transplantation, transjugular intrahepatic portosystemic shunt(TIPS) insertion or May 2023. Multivariate analysis models were used to determine independent predictors of the presence and severity of LVDD.126Spearman’s test was used for correlation of E/e’ ratio with other variables whereby correlation coefficient (r) >0.6 indicated strong correlation. The incidence risk of HRS development and liver-related death according to severity of diastolic dysfunction was estimated using Kaplan-Meier analysis and differences were compared by the log rank test. A p value of <0.05 was considered statistically significant. Results: LVDD was diagnosed in 142 (66%) patients with ascites: grade 1 in81 (57%), grade 2 in 43 (30.3%), and grade 3 in 18 (12.7%). Only 9 (11.6%)patients without ascites had LVDD (p<0.001 vs. those with ascites): grade 1and 2 in 8 and 1 patients, respectively. All patients had a normal LVEF at rest. Among patients with ascites, serum LBP levels were significantly higher in those with grade 1 and grade 2/3 LVDD than in patients without LVDD(p=0.001 and p<0.001, respectively). Patients with grade 2/3 LVDD had significantly higher LBP levels compared to those with grade 1 (p<0.001).Serum TNF-α and IL-6 levels were significantly higher in patients with grade2/3 LVDD compared to patients in the other two subgroups (p<0.001).Patients with grade 2/3 LVDD showed significantly lower MAP and CO compared to patients in the other two subgroups (p<0.001). PRA was significantly higher in patients with grade 1 and grade 2/3 LVDD than in those without LVDD (p<0.001). Patients with grade 2/3 LVDD had significantly higher PRA compared to those with grade 1 (p<0.001). Plasma aldosterone and noradrenaline levels were significantly higher in patients with grade 2/3LVDD compared to patients in the other two subgroups (p<0.001). GFR and RBF did not differ between patients with grade 1 and those without LVDD. patients with grade 2/3 LVDD had significantly lower GFR and RBF compared to those with grade 1 (p<0.001 and p=0.005, respectively) and those without LVDD (p<0.001). Serum LBP (p=0.004) and PRA (p=0.03) were independently associated with the presence of grade 1 LVDD. Independent factors associated with the presence of grade 2/3 LVDD were serum LBP(p<0.001), serum TNF-α (p=0.01), CO (p=0.04), PRA (p<0.001), plasma noradrenaline (p=0.003), and GFR (p=0.009). Finally, serum LBP (p<0.001),PRA (p=0.005), and GFR (p=0.01) were independently associated with the severity of LVDD. We found a strong significant correlation of E/e’ ratio with127serum LBP (r=0.731; p<0.001), PRA (r=0.714; p<0.001), and GFR (r=-0.609;p<0.001) among patients with LVDD and ascites. E/e’ was less strongly but significantly correlated with MAP (r=0.565; p=0.008), CO (r=0.478; p=0.01),plasma aldosterone (r=0.416; p=0.03), plasma noradrenaline (r=0.502;p=0.03), TNF-α (r=0.390; p-0.01), serum IL-6 (r=0.327; p=0.02), and RBF(r=0.316; p=0.04). Among 96 patients treated with propranolol, 64 were randomized to switch to carvedilol and 32 continued propranolol. Diastolic function improved significantly at 6 months in patients treated with carvedilolas shown by the significant decreases in E/e’ ratio (p=0.04) and LAVI (p=0.03)and the significant increase in E/A ratio (p=0.04) along with significant increases in SVR and GFR (p=0.03 and p=0.04, respectively). No significant changes were noted in patients who continued on propranolol. Recurrence of ascites was observed significantly more frequently in patients with LVDD compared to those without: 36/142 (24.6%) vs. 10/73 (13.6%), p=0.02. New episodes of variceal bleeding or hepatic encephalopathy occurred similarly in both patient groups. HRS was diagnosed in 27 patients after a mean follow-up period of 22.8±2.1 (range: 5-46) months. The 5-year occurrence of HRS was higher in patients with LVDD than in those without (23.3% vs. 9%;p=0.05).The 5-year probability of developing HRS was 35.5% in patients with grade2/3 LVDD compared to 14.4% in those with grade 1 (p=0.01) and 9% inpatients without LVDD (p=0.002). The occurrence of HRS did not differ between patients with grade 1 and those without LVDD. Eighty-two patients died during a mean follow-up of 38.8±1.8 (range: 3–107) months due to liver related causes: variceal bleeding (n=23), HRS (n=18), bacterial infections(n=17), hepatocellular carcinoma (n=12), and liver failure (n=12). Patients with LVDD hade worse survival than those without (41.6% vs. 64.6% at 5years;p=0.02). Patients with grade 2/3 LVDD had significantly lower 5-yearsurvival rates than those without (28.2% vs. 64.6%;p=0.002) and patients with grade 1 LVDD (28.2% vs. 53.3%;p=0.03). Patients with grade 1 LVDD had lower survival than those without LVDD but the difference did not reach statistical significance. Conclusions: LVDD occurred significantly more frequently in patients with ascites than in those without. The occurrence and severity of LVDD in patients128with cirrhosis and ascites was closely related to inflammatory activity. Advanced LVDD was associated with baseline circulatory and renal dysfunction, favoring recurrence of ascites, HRS development, and increased mortality. Carvedilol may improve diastolic function in patients with cirrhosis and LVDD.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Christaki, Maria
  • Χρηστάκη, Μαρία

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/59008

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Christaki, Maria; Χρηστάκη, Μαρία. Διαστολική δυσλειτουργία της αριστερής κοιλίας στην κίρρωση: συχνότητα, διερεύνηση της συσχέτισης με την συστολική λειτουργία, την νεφρική λειτουργία και την κλινική έκβαση και ο ρόλος της ενδοτοξιναιμίας και των β-αποκλειστών. University of Ioannina, 2024. http://hdl.handle.net/10442/hedi/59008